Literature DB >> 21351288

Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.

T Daimon1, S Zohar, J O'Quigley.   

Abstract

The continual reassessment method (CRM) is a method for estimating the maximum tolerated dose in a dose-finding study. Traditionally, use is made of a single working model or 'skeleton' idealizing an underlying true dose-toxicity relationship. This working model is chosen either by discussion with investigators or published data, before the beginning of the trial or simply on the basis of operating characteristics. To overcome the arbitrariness of the choice of such a single working model, Yin and Yuan (biJ. Am. Statist. Assoc. 2009; 104:954-968) propose a model averaging over a set of working models. Here, instead of averaging, we investigate some alternative Bayesian model criteria that maximize the posterior distribution. We propose three adaptive model-selecting CRMs using the Bayesian model selection criteria, in which we specify in advance a collection of candidate working models for the dose-toxicity relationship, especially initial guesses of toxicity probabilities, and adaptively select the only one working model among the candidates updated by using the original CRM for each working model, based on the posterior model probability, the posterior predictive loss or the deviance information criteria, during the course of the trial. These approaches were compared via a simulation study with the model averaging approach.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21351288     DOI: 10.1002/sim.4054

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Interplay of priors and skeletons in two-stage continual reassessment method.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2012-08-15       Impact factor: 2.373

2.  A nonparametric Bayesian method for dose finding in drug combinations cancer trials.

Authors:  Zahra S Razaee; Galen Cook-Wiens; Mourad Tighiouart
Journal:  Stat Med       Date:  2022-01-25       Impact factor: 2.373

3.  A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.

Authors:  Haitao Pan; Ying Yuan
Journal:  Stat Med       Date:  2016-03-16       Impact factor: 2.373

4.  Performance of two-stage continual reassessment method relative to an optimal benchmark.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Clin Trials       Date:  2013-10-01       Impact factor: 2.486

5.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.

Authors:  Suyu Liu; Guosheng Yin; Ying Yuan
Journal:  Ann Appl Stat       Date:  2013-12-01       Impact factor: 2.083

6.  A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research.

Authors:  Chunyan Cai; Mohammad H Rahbar; Md Monir Hossain; Ying Yuan; Nicole R Gonzales
Journal:  Contemp Clin Trials Commun       Date:  2017-05-06

7.  Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.

Authors:  Caroline Petit; Adeline Samson; Satoshi Morita; Moreno Ursino; Jérémie Guedj; Vincent Jullien; Emmanuelle Comets; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2016-10-05       Impact factor: 3.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.